HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sun, J. Articles by Nishi, Y. Search for Related Content PubMed PubMed Citation Articles by Sun, J. Articles by Nishi, Y.

Molecular Evolution of Catalytic Antibodies in Autoimmune Mice¹

Laboratory of Life Science and Biomolecular Engineering, Japan Tobacco, Yokohama, Kanagawa, Japan

Catalytic Abs (catAbs) preferentially evolved in autoimmune MRL/MPJ-lpr/lpr (MRL/lpr) mice upon immunization with the phosphonate transition-state analogue (TSA), but this did not happen in normal BALB/c mice. The majority of the catAbs from MRL/lpr mice were from several independent clones of the same family. Most of them had a lysine at position 95 in the heavy chain (H95), which is at the junctional region. This residue, which interacts with the phosphonate moiety of the TSA and presumably is involved in the catalytic activity, was not changed even after expansive evolution following multiple mutations. By contrast, the majority that arose from BALB/c mice were the non-catAbs, which were quite different in the sequence from the catAbs from MRL/lpr mice, but they were clonally related to one another, so most of them were originated from a single clone. In the MRL/lpr mice, the catalytic subsets that existed in the initial repertoire were effectively captured by the phosphonyl oxygens in the TSA by interacting with the lysine at H95. In the BALB/c mice, however, another noncatalytic subset with only the binding capability directed to a moiety other than the phosphonate moiety was alternatively evolved, because of the lowest abundance or elimination of the catalytic subsets.

This article has been cited by other articles:

				Y. Nishi, N. Yamamoto, K. Shimazaki, N. Takahashi-Ando, H. Kakinuma, S. Jialin, S. N. Ruzheinikov, T. A. Muranova, D. W. Rice, and Y. Kajihara Mechanistic Analysis of the Phosphonate Transition-state Analogue-derived Catalytic and Non-catalytic Antibody J. Biochem., October 1, 2007; 142(4): 421 - 433. [Abstract] [Full Text] [PDF]

				S. Paul, S. Planque, Y.-X. Zhou, H. Taguchi, G. Bhatia, S. Karle, C. Hanson, and Y. Nishiyama Specific HIV gp120-cleaving Antibodies Induced by Covalently Reactive Analog of gp120 J. Biol. Chem., May 23, 2003; 278(22): 20429 - 20435. [Abstract] [Full Text] [PDF]

				Y. BANGALE, S. KARLE, S. PLANQUE, Y.-X. ZHOU, H. TAGUCHI, Y. NISHIYAMA, L. LI, R. KALAGA, and S. PAUL VIPase autoantibodies in Fas-defective mice and patients with autoimmune disease FASEB J, April 1, 2003; 17(6): 628 - 635. [Abstract] [Full Text] [PDF]